Headlines about Genomic Health (NASDAQ:GHDX) have trended somewhat positive on Thursday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Genomic Health earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.2159611800725 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
A number of equities research analysts have recently commented on GHDX shares. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Piper Jaffray Companies restated a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Canaccord Genuity decreased their price objective on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 15th. Finally, Cowen and Company restated a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $32.00.
Shares of Genomic Health (GHDX) traded up 1.42% during trading on Thursday, hitting $32.94. 111,658 shares of the company’s stock were exchanged. Genomic Health has a 12-month low of $26.37 and a 12-month high of $34.02. The company’s market cap is $1.14 billion. The company has a 50-day moving average of $32.08 and a 200-day moving average of $31.77.
Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The business had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period last year, the company posted ($0.18) EPS. On average, equities analysts expect that Genomic Health will post ($0.04) earnings per share for the current fiscal year.
In related news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $30.57, for a total transaction of $152,850.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider James J. Vaughn sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total value of $244,720.00. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock worth $1,022,620 over the last ninety days. 46.20% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/10/26/genomic-health-ghdx-given-news-impact-rating-of-0-11.html.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.